Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19
Biykem Bozkurt, Richard J. Kovacs, Bob Harrington
Topics & Concepts
MedicineAdverse effectHeart failureDiseaseCoronavirus disease 2019 (COVID-19)Downregulation and upregulationRenin–angiotensin systemAngiotensin Receptor BlockersInternal medicineIntensive care medicineAngiotensin-converting enzyme 2Blood pressureInfectious disease (medical specialty)GeneBiochemistryChemistryCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19